The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma

Polatuzumab vedotin (Pola) is an antibody–drug conjugate that targets the B‐cell antigen CD79b and delivers monomethyl auristatin E (MMAE). It is approved in combination with bendamustine and rituximab (Rit) for relapsed/refractory diffuse large B‐cell lymphoma (r/r DLBCL). Understanding the molecul...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawasaki, Natsumi, Nishito, Yukari, Yoshimura, Yasushi, Yoshiura, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematological Malignancy–Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796291/
https://www.ncbi.nlm.nih.gov/pubmed/35764309
http://dx.doi.org/10.1111/bjh.18341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796291/
https://www.ncbi.nlm.nih.gov/pubmed/35764309
http://dx.doi.org/10.1111/bjh.18341

Ejemplares similares